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Background: Sarcomas of the uterus have been viewed as rare. Previously known
as Malignant Mixed Mesodermal Tumour (MMMT), the preferred term is now
carcinosarcoma (CS).
Obesity, unopposed oestrogen exposure and Tamoxifen have all been associated
with epithelial endometrial carcinomas. The literature has been scanty in its
mention of endometrial carcinosarcomas developing in patients treated with
Tamoxifen.
The ﬁrst National Surgical Adjuvant Breast and Bavel Project (NSABP) report
[1] did not make speciﬁc mention of an increased incidence of uterine CS in their
cohort of patients, although does note an increased incidence of endometrial
cancer in patients taking Tamoxifen for breast cancer. The most recent update
from the NSABP, looking at more than 17 000 women in a number of NSABP
trials [2] does report an increased risk of CS. Bergman again reports only a few
cases [3]. There have also been a number of small case series and reports, the
largest including 7 cases [4].
Prompted by our own experience and new data emerging regarding the common
aetiology of endometrial carcinosarcomas and carcinomas, we decided to review
our past four years of experience.
Patients methods: Nearly 100 cases (91) of endometrial /cervical carcinosarcoma,
endometrial stromal sarcoma and leiomyosarcoma have been registered with
the West of Scotland Gynaecological Cancer Managed Clinical Network
(MCN). All newly diagnosed cases are reported to the MCN. We are conﬁdent
that this represents a very high, if not total, representation of all uterine
sarcomas treated in the West of Scotland in the past four years. Basic
demographic data were collected on these patients including age. In addition, a
previous history of malignancy, or any prior exposure to pelvic irradiation (as
might have been used to induce a radiation menopause) was recorded. From
this group, 19 patients with a history of breast cancer were identiﬁed and their
case notes reviewed.
Results: Of these 19 patients, 17 had a history of Tamoxifen exposure and were
examined further.
Their average age was 66 years (range 54–78 years) at the time of their breast
cancer being diagnosed, and 75 years (range 63–85 years) at the time of their CS
being diagnosed. 16 patients had a uterine CS and one cervical. Nine patients
had stage 1/2 disease and eight stage 3/ 4.
Average length of time between commencing Tamoxifen and diagnosis of CS
(latency period) was 8.8 years (range 2–15 years). The median length of time
between stopping Tamoxifen and the diagnosis of CS was 38 months in 12
patients (range 3–72 months), not known in 2 patients, and in 3 patients
Tamoxifen was stopped at the time of diagnosis of CS.
Average duration of Tamoxifen use was 6.1 years (range 5–10 years) in 14 patients.
One patient had 2 phases of exposure to Tamoxifen. In two patients, precise details
were unavailable. All patients received 20 mg of Tamoxifen daily for the duration
of their time on it, with the exception of one patient who received varying doses for
8 years. No patient had a history of prior pelvic irradiation. One patient had a
previous history of melanoma, but no details were available.
Current follow-up data were available for all patients. One patient is still
undergoing treatment, in 16 others; the median length of follow-up was nine
months (range 2–22 months). Of these, 12 patients have died (11 of their disease,
1 from causes unclear). 5 are alive; 1 is undergoing palliative chemotherapy, 2
have liver metastases (1 from breast cancer, 1 from CS), and two are disease-free.
The prevalence of other second malignancies in the series of patients with a
diagnosis of uterine CS was also noted. 2 patients had a prior history of bladder
cancer, 1 ovarian carcinoma, 1 head and neck malignancy, 1 Non-Hodgkin’s
lymphoma, and one cervical intra-epithelial neoplasia grade 3. One patient had a
history of artiﬁcial radiation menopause (ARM) 20 years previously for the
treatment of menorrhagia.
Discussion: It appears that the association between breast cancer, treatment with
Tamoxifen and CS, is perhaps stronger than previously appreciated, and the
latency period between starting Tamoxifen and developing CS longer (8.8 years).
The importance of clinicians being alert to such diagnoses is thus emphasised
and a need for surveillance programmes longer than are currently practiced in
most areas is suggested.
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